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The expanding and established literature that correlates tumor
infiltrating lymphocytes (TILs) with outcomes of patients with solid
tumors has contributed greatly to the appreciation of the interaction
between the host immune system with neoplastic growth. This
analysis has been limited to specific tumors, such as melanoma and
ovarian cancer, and our understanding of TILs in relation to many
other malignancies has yet to be explored. We review one less well
studied malignancy, head and neck squamous cell carcinoma
(HNSCC), and the initial attempts to examine the impact of TILs on
outcomes of these patients. To provide a context for the discussion of
TILs and HNSCC, we first review the epidemiology, relevant head
and neck anatomy, immune responses and discuss the historical data
regarding the unique immunobiology of these tumors. Finally, with
this perspective, we describe our current understanding of tumor
infiltrating lymphocyte data for head and neck cancers.

Keywords: human, head and neck cancer, tumor-infiltrating
lymphocytes, prognosis, therapy

Head and neck cancer: A clinical perspective
Pathologically, the vast majority of tumors (95%) that arise in
the head and neck region are squamous cell carcinomas arising
from the upper aerodigestive tract epithelium. The progressive
local growth of head and neck squamous cell carcinomas
(HNSCCs) impinge on the highly critical functions of speech,
swallowing and respiration. Current therapies, whether the
modality is surgery alone or combined with radio- or chemoradiotherapy, leave many of these patients with significant
functional deficits exacting a unique physical, social and
emotional toll. Although significant advances in the areas of
reconstructive surgery,
minimally
invasive
surgery,
chemotherapy and monoclonal antibody therapy have been
achieved in the last two decades, the overall survival rates for
patients with these cancers has been minimally affected.
Other tumors of the head and neck region include melanomas
where the prognostic significance of tumor infiltrating
lymphocytes (TILs) has been clearly established (1, 2). In
addition, nasopharyngeal squamous cell carcinomas (NPCs) are
a group of head and neck tumors that have a biological behavior
quite distinct from conventional HNSCCs. Therefore, as these
tumors are strongly associated with Epstein-Barr virus, are
geographically localized and as a whole are managed differently
than HNSCCs (3-5), they will not be considered in this review.

Epidemiology
HNSCCs are a significant public health entity in that they
claim 11,000 lives a year in the United States and represent one
of the top ten cancers worldwide (6, 7). The overall 5-year
survival rate for patients with HNSCC is approximately 50%.
Despite significant advances in the medical and surgical
treatment of these cancers, this statistic has remained stable for
decades.
The major independent risk factors for development of these
tumors are tobacco and alcohol abuse. Many patients have
simultaneous addictions to both, which synergize to greatly
increase the risk of tumor development. The habits of betel nut
and gutkha chewing and reverse smoking, common practices in
South Asia, are also contributing carcinogenic insults. The
general decrease in smoking in North America has reduced the
incidence of these cancers; however, there has been an increased
incidence of oral tongue, tonsil and base of tongue carcinomas
in patients under the age of 45, an increase that has been
attributed to HPV infection in the latter two sites [reviewed in
(8, 9)].

Immunoediting in head and neck cancer
Human immunosurveillance of HNSCC

Our expanding concepts about TILs and their relation to
patient prognosis have occurred in the context of a better
understanding of immunosurveillance. In the last fifteen years,
this previously abandoned concept has been resurrected by
analysis of multiple tumor models in mice deficient in a variety
of immunologically relevant cells and molecules, including T
and B lymphocytes, IFN-γ, STAT1 and perforin [reviewed in
(10)]. These data revealed that the immune system does indeed
protect against the development of primary and chemical
carcinogen-induced cancers. This result, however, raised the
question of why organisms with intact immune systems develop
neoplastic disease. The finding that addressed this issue came
from analysis of tumors that arose in wild-type hosts compared
to immunodeficient RAG2-/- lymphocyte deficient hosts. All
tumor cells (whether wild-type or RAG2-/- derived) formed
progressively growing sarcomas in RAG2-/- mice. However,
when assessed for their capacity to form tumors upon
transplantation into wild-type syngeneic hosts, tumors derived
from immunocompetent hosts were significantly more
tumorigenic than those from immunodeficient hosts. Thus, the
immune system protects against the development of tumors and
yet drives the generation of tumors that have developed
mechanisms to evade elimination. These data have been codified
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as the "Cancer Immunoediting" hypothesis which includes as its
first phase the older concept of tumor immunosurveillance
[reviewed in (10)]. One of the key components in these studies
was the ability to experimentally manipulate mice, which
allowed the generation of incontrovertible evidence supporting
the Cancer Immunoediting hypothesis. However, similar
evidence in human tumors can only be gained indirectly and
TIL analysis is one of the cornerstones of these studies in
humans as exemplified by the studies of Galon, Fridman and
Pagès (11-13).
One clear indication of the contribution of the immune system
in controlling HNSCC is the relative increase in incidence in the
context of acquired or iatrogenic immunodeficiency. King et al.
(14) identified premalignant lip leukoplakia in 13% of renal
transplant patients as compared to 0.6% of control age- and sexmatched individuals. Of the renal transplant patients with
leukoplakia, a majority demonstrated dysplastic conversion and
10% of these patients (i.e. 2/21 patients with leukoplakia) had
squamous cell carcinoma. Many other reports examining
databases of transplant recipients have confirmed this increased
incidence of lip (15, 16) and other cancers (17). In addition,
analysis of patients who underwent bone marrow
transplantation
for
hematologic
malignancies
also
demonstrated a 17.4-fold increased risk for oral cancer, which
was second only to the risk of liver cancer development (18).
Again, many other studies (which are not mentioned here due to
space limitations) have confirmed these general findings [for
example see (19)]. An additional contributing risk factor for
buccal cancers in patients who have undergone hematopoietic
stem cell transplantation is chronic graft versus host disease
(GVHD) that may contribute to local inflammation and tumor
development (20). Due to the relatively recent appreciation of
the contribution of HPV to HNSCC, all of these studies lack
documentation of HPV status in lip and oral tumors in the
transplant recipients. The increase in infection-related cancers
in HIV positive and transplant patients has received recent
attention (21). We discuss this topic in the HPV section below.
Anatomy relevant to HNSCC immunosurveillance

The complex anatomy of the upper aerodigestive tract allows
for multiple functions including mastication, deglutition,
phonation and airway maintenance. This portal also serves as
the entry point to both the gastrointestinal and respiratory
systems. Thus, cancerous growths in any part of the upper
aerodigestive tract impinge on multiple overlapping functions.
The mucosal subsites of the head and neck where tumors
develop include the nasopharynx, paranasal sinuses, oral cavity,
oropharynx, larynx and hypopharynx. Patients with tumors that
develop in the larynx or oral cavity, where subjective symptoms
manifest earlier, have a clinical behavior quite different than
patients with tumors in the hypopharynx. Patients present much
earlier because of symptoms such as hoarseness for laryngeal
lesions or masses in the oral cavity, whereas lesions in the
hypopharynx are tolerated much longer and thus these patients
typically present with advanced disease. This varied clinical
presentation must also be considered in any TIL analysis of
tumor samples.
The associated lymphatic drainage of the upper aerodigestive
tract tumors serves as the first echelon of regional metastatic
cancer spread. The lymphatic chains within the neck are divided
into 6 major levels−level I includes the submental and
submandibular nodes, levels II through IV encompass the
jugular chain lymph nodes by dividing the nodes into three
equal segments, level V nodes are in the "posterior triangle"
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which track with the eleventh cranial nerve as it leaves the
sternocleidomastoid muscle and heads towards the trapezius
muscle and, finally, level VI nodes are the central compartment
nodes which surround the trachea near the thyroid gland. More
recently, tumor involvement in the retropharyngeal lymph
nodes (which include the node of Rouviere) has garnered
attention as a site of tumor metastasis that was often missed in
older surgical approaches (22, 23). A large body of literature
based on retrospective analysis of primary tumors and their
associated resected lymph node dissections showed that specific
lymphatic groups serve as recipients of regional metastases (2426). Thus, for example, tumors of the oral cavity (lip and
anterior floor of the mouth) drain to level I nodes whereas tonsil
tumors drain to the level II nodes. Lymph node involvement
with tumor is one of the worst prognostic factors for patients
with HNSCC (27)−for example, patients with oral tongue cancer
have close to a 50% decrease in survival if cervical lymph nodes
are involved with tumor at initial presentation [reviewed in
(28)]. In addition, patients with extracapsular spread of tumor
out of the lymph node have been shown to be at high risk for
recurrent tumor (29-32). The underpinnings of the propensity
of certain tumors for lymph node involvement remains under
investigation but likely involves a combination of dependent
drainage (i.e. certain subsites have easier access to lymphatic
pathways than other sites) and specific molecular pathways.
The major lymphoid tissues in direct contact with the
epithelium giving rise to HNSCC are encompassed in the
Waldeyer's ring, which includes the laterally located palatine
tonsils, the inferiorly positioned base of the tongue with lingual
tonsillar tissue, and finally the superiorly based nasopharyngeal
adenoid pad. How these structures contribute to immune
responses in the oral cavity is still undefined (see below).
Importantly, HNSCC originating within these regions
encompass a significant number of diagnosed cases. Tumors
arising in the oropharyngeal and nasopharyngeal subsites may
have a constitutive heavy lymphocyte content complicating
immunohistochemical analysis of lymphocytes within tumors.
A second consideration for these subsites is that specific viral
associations with nasopharyngeal carcinoma (Epstein-Barr
virus or EBV) and oropharyngeal carcinoma (human papilloma
virus or HPV) may reflect a viral antigen-specific immune
response to these tumors rather than to host-derived tumorspecific antigens (see the separate section on HPV-related
tumors).
Finally, the specific lymphatic drainage of the subsites is
variable, thus, early regional lymphatic metastasis from
supraglottic HNSCC is typical whereas glottic cancers manifest
a delayed lymphatic involvement. In addition, the supraglottis is
considered to be a midline structure and thus lymph flow is
directed to bilateral regional lymphatic structures. It is unclear
whether this type of increased drainage to regional lymphatics
by one subsite results in an augmented histologic immune
response. Clinically, patients with supraglottic tumors do not
fare as well as similar stage glottic tumors. Thus, a hypothetical
increase in exposure to the regional lymphatics does not
translate to better outcomes.
Immunosurveillance of HPV-associated tumors

A significant amount of scientific literature supports an
oncogenic role for HPV as a causative agent in oropharyngeal
cancer leading some authors to suggest that we will, or already
have, reached epidemic proportions (9). As many other excellent
reviews detail the biology, clinical presentation, behavior and
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Table 1

HNSCC tumor antigens.

treatment of these tumors (9, 33, 34), we limit our discussion to
the potential immune responses manifest as TILs.
The successful development of an HPV vaccine that targets the
key oncogenic subtypes 16 and 18 has garnered a significant
amount of lay press attention, focused the public's awareness on
cervical cancer etiology and generated a fierce debate about this
intervention in prepubescent females [for example see (35)].
However, the current strategy to vaccinate young girls does not
take into consideration the vast potential benefit of also
including young men in this public health campaign. For
unclear reasons, men disproportionately (at a 2:1 ratio) develop
HPV-associated oropharyngeal tumors. Although the vaccine is
not approved for use in males, a benefit in oropharyngeal and
genital tumors would be gained with immunization. Increased
public awareness of HPV associations with oropharyngeal
cancer [for example see (36)] will likely lead to further calls for
including all youth prior to sexual maturity.
Clearly, in TIL analysis of HNSCC, virus-associated tumors
must be specifically identified as the infiltrate in these tumors
may be a reflection of a host T cell response to viral gene
products. No studies have specifically addressed this issue but
several investigators have examined the peripheral blood of
patients with HNSCC for the presence of virus-specific T cells
using tetramer technology. Both Albers et al. (37) and
Hoffmann et al. (38) identified a 2-3 fold elevated level of HLAA*201 restricted viral E7-specific T cells in the peripheral blood
of patients with HPV+ HNSCC versus patients with HPVHNSCC or normal controls. Interestingly, Ferris and colleagues
(37) found that E7-specific cytotoxic T lymphocytes (CTLs)
expanded from peripheral blood did not directly recognize an
HLA-A*201 expressing HPV+ tumor cell line. They found a
significant decrease of antigen processing machinery
components in this cell line and in primary HPV+ tumors and
determined that interferon-gamma (IFN-γ) pre-treatment of the
cell line greatly enhanced CTL recognition. Thus, these
investigators postulated that although virus-specific CTLs exist
in HPV+ HNSCC patients, immune escape occurred due to the

inability of these CTLs to recognize the tumor. As we gain a
better understanding of HPV antigens and HNSCC immune
evasion mechanisms, these viral antigens may emerge as a
means to target this subset of tumors.
Tumor antigens and recognition of HNSCC

Some of the most significant data supporting immune
recognition of tumors derives from the identification of specific
tumor antigens. The HPV-derived antigens described above
obviously develop in the context of host recognition of viral
machinery. However, similar to other tumors, efforts to identify
novel tumor-derived products using serological identification or
tumor-specific cytotoxic T lymphocytes (CTLs) have resulted in
the discovery of both novel HNSCC-specific and common
cancer/testis (CT) antigens (39-47). These studies are
summarized in Table 1. Immunotherapy using these antigens
for vaccination is at an early stage in HNSCC (48).
Development of oral tolerance in anti-HNSCC immune responses

Just as a grasp of the gross anatomy of the head and neck is a
prerequisite for understanding the biology of HNSCC,
understanding the local immunologic "anatomy" and immune
response is important in the context of examining TIL
responses. Similar to the gastrointestinal tract and brain, there
are important differences in the local response that are a
consideration in how an individual develops a reaction to a
growing tumor, and this may play a role in the development of
any immunotherapeutic strategy. However, as opposed to the
gastrointestinal tract, fewer studies are available, and the vast
majority is derived from the dental literature which is focused
on chronic adult periodontitis in the oral cavity, or studies where
application of allergens to the nasal mucosa is used to examine
immune responses. We review some of these studies due to their
relevance in host responses to cancer development, especially in
the context of tolerogenic mechanisms driven by oral antigen
exposure.
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The upper aerodigestive tract environment is bathed in
approximately 1 liter of saliva per day which helps in digestion,
via the α-amylase and lingual lipase enzymes, and in deglutition
(49). Saliva also serves an immunologic function in that it is rich
in anti-microbial peptides and IgA. The mucosa of the oral
cavity and oropharynx also acts as a barrier where one finds
keratinization over areas that encounter shear forces (such as the
tongue and hard palate) with the remainder having a
nonkeratinized epithelium [reviewed in (50)]. This barrier
function is distinct from skin in that there is significant
permeability and vascularization, which presumably allows
sampling of antigens in the oral cavity. Similar to the bacterial
load within the gastrointestinal (GI) tract, the oral cavity has
over 500 distinct bacterial species that exist in a commensal
relationship (51). The development of tolerance to these bacteria
and the lack of inflammatory reactions in the oral cavity clearly
suggests that a mechanism to induce tolerance exists that likely
parallels that seen in the GI tract.
Here a distinction must be drawn between oral tolerance
driven by gut exposure to antigens and oral mucosal tolerance
where the structures in the oral cavity drive
immunosuppression. The former, which has been extensively
reviewed, is a well-studied mechanism whereby GI tract
antigens are sampled by specific cells [including CX3CR1+
dendritic cells (52)], transported to mucosa-associated
lymphoid tissues (MALT - including Peyer's patches and
mesenteric lymph nodes) and subsequently induce tolerogenic
responses via specific cell populations (i.e. IL-10 producing
regulatory T cells) and cytokines such as TGF-β. These
mediators in turn suppress inflammatory responses driven by
Th1 and Th17 cells, which allows tolerance to commensal
organisms and food/environmental antigens. In contrast, oral
mucosal tolerance is a less well-defined mechanism where
similar sampling and transport to undefined inductive sites also
induces a tolerogenic state. This is well illustrated in the example
of adolescents who have nickel containing dental appliances
who then demonstrate reduced T cell mediated responses (53).
More recently, sublingual immunotherapy (SLIT) has been
gaining popularity as a means to induce tolerance to
environmental allergens [reviewed in (54, 55)].
Dendritic cells (DCs) are at the front line of the immunologic
infrastructure and have initial contact with antigen. Studies in
the sublingual region of BALB/c mice identified a rich network
of CD11b+ CD11c+ cells that were also MHC class II+,
expressed the CD40, CD80 and CD86 costimulatory molecules,
and the CCR6 chemokine receptor (56)−cellular features which
are similar to Langerhan's cells found in skin. Sublingual
administration of ovalbumin induced antibody responses,
specific cytokine expression and T cell proliferation but required
a cholera toxin adjuvant to achieve significant levels. Studies in
humans have also identified similar DC populations [reviewed
in (57)], again suggesting that these cells serve as the sentinels
for foreign invaders in the oral mucosa.
Once these DCs sample oral antigens, the inductive site(s)
where the immune response is initiated is most likely in the
cervical lymph nodes. Inductive sites for tolerance in the gut
were identified using mice deficient in various components of
the lymphotoxin family and revealed that mesenteric lymph
nodes are critical for inducing tolerance (58) whereas the role of
Peyer's patches was felt to be dispensable. The parallel MALT in
the head and neck in humans is represented by the lymphoid
tissue in Waldeyer's ring. Although not providing definitive
proof (as not all oropharyngeal lymphoid tissue is removed),
surgical removal of adenoids and tonsils in humans has gone on
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for decades with no evidence of increased infections,
inflammation or autoimmunity. Clearer evidence has been
described in mice where tolerance to a nasal challenge with
ovalbumin was absolutely dependent on the presence of cervical
lymph nodes (59). Interestingly, transplanting functioning
peripheral axillary lymph nodes into the cervical region of mice
that had all neck lymph nodes removed did not allow for
development of tolerance. However, control cervical lymph
node transplants into similar mice did show induction of
tolerance suggesting that regional differences in specific lymph
node architecture can dictate this immune response. Studies to
define the inductive sites in mice using the oral cavity as the
initiating site have not been performed to date. Thus, although
many of the specifics of oral mucosal tolerance have not been
defined, significant parallels and differences are emerging with
respect to the better defined mechanisms in the gut.
With respect to developing cancers in the upper aerodigestive
tract, how does the propensity of this site for tolerance induction
to commensal organisms and environmental antigens relate to
the host response to nascently transformed cells? Although
speculative, we suggest that this local immune response may
reduce the host response to developing tumors, which obviously
would be reflected in any analysis of tumor infiltrating
lymphocytes. This concept has been proposed for the gut where
intra-cecal injection of a BALB/c syngeneic colon carcinoma
showed an increased growth rate compared to the subcutaneous
flank site (60). These investigators hypothesized that tumor
exposure through the MALT would result in systemic
immunosuppressive effects and indeed this was borne out as
they found an increased concentration of immunosuppressive
TGF-β in the serum of mice 14 days after subserosal cecal
implantation of tumor cells relative to the subcutaneous site.
O'Sullivan and colleagues (61, 62) have proposed the same idea
in relation to cancers of the foregut.
Escape: How HNSCC evades the immune response

Tumor cells from all sites have evolved multiple pathways for
both active and passive immune evasion [reviewed in (63)] and
HNSCC echoes many of these themes [reviewed in (64)]. Many
early studies examining global immunosuppression induced by
cancers primarily involved patients with HNSCC (65-69). These
studies utilized reactivity to 2,4-dinitrochlorobenzene (DNCB)
as an indicator of cell-mediated immune response, and the
general sense at that time was that patients with HNSCC were
more immunocompromised than patients with other cancers
and that worsening reactivity to DNCB correlated with a poorer
prognosis for patients (66, 67).
A better understanding of the molecular and cellular basis of
immune responses and regulation has led to a more detailed
analysis of the underpinnings of these early studies. Several
pathways utilized by HNSCC have been delineated to account
for tumor immune evasion [reviewed in (64)]. Some of these
mechanisms include immunosuppressive myeloid-derived
suppressor cells (MDSCs) (64, 70), decreased HLA class I
expression by tumor cells (71-74), tumor-induced T cell
apoptosis (75), regulatory CD4+ CD25+ T cells (76, 77),
galectin-1 expression by tumor cells (78, 79) and tumor-induced
senescent T cells with suppressor function (80). The
interrelationships between these putative mechanisms and how
they may influence TILs has not been explored in detail.
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Table 2

Studies on TILs in HNSCC.

Current status of TIL analysis in HNSCC
The available studies on TILs in HNSCC are not definitive
(summarized in Table 2). The major limitation in existing
reports is the low number of patient samples available for
analysis and the heterogeneity in tumor stages, which eventually
impacts the interpretation of histologic data. Given this
backdrop, specific studies have arrived at conclusions either
supporting or dismissing the prognostic value of lymphocyte
infiltration into HNSCC.
As for many other tumor types, initial prognostic studies on
HNSCC were limited to subjective observation of lymphocyte
infiltration on H&E (hematoxylin and eosin) stained tumor
specimens. One detailed study that illustrates this type of
analysis assessed lymphocyte infiltration into over 200 oral
squamous cell carcinomas (81). Using multivariate analysis,
these investigators identified that a weak or limited lymphocyte
response at the tumor and stromal margin was associated with
increased locoregional recurrence and decreased overall
survival. Many other pathologic criteria were also examined but
the lack of definition of what actually constitutes the
lymphocytic infiltrate demonstrates the limitation of this
approach.
The first studies examining specific lymphocytes were
performed in the 1980s using newly available monoclonal
antibodies for specific T cells (82). Using a selected cutoff
number of cells per high power field (HPF), Wolf and colleagues
identified a survival benefit for patients who had intra-tumoral
CD4+ T cell, but not CD8+ T cell, infiltration. However, the
significant limitations in this study included a 9.5 month
average follow-up (range 2-25 months), limited tumor numbers
and heterogeneous tumor sites. The largest subset of tumors in
their 40-patient study was a group of 10 patients with oral cavity
tumors. In contrast, Guo and colleagues (83) examined 26
patients, again from diverse subsites, and found a trend towards
improved survival with increased numbers of all T lymphocyte
subsets but statistical significance was not achieved. Finally,
Snyderman et al. (84) performed a fluorescence activated cell
sorter (FACS) based assay on TIL preparations from 16 patients
with various stages of HNSCC. These investigators identified a

better prognosis in patients who had CD4/CD8 ratios less than 1
and therefore suggested that the lack of CD8 cells in the tumor
may have led to poorer outcomes. Thus, these early attempts at
analyzing TILs in HNSCC yielded some provocative but mixed
results, and ultimately were inconclusive due to the limitations
described.
Following these initial studies, the attention of immunologists
studying HNSCC turned away from potential prognostic
information provided by TILs towards the incapacitating effects
of the tumor on host immune cells. However, with the renewed
interest in TIL studies in the current decade, more specific
evaluation approached the definition of the composition of the
cellular infiltrate, either directly or indirectly, in the context of
studies on immunosuppressive molecules. Sewell and colleagues
(85) generated a tissue microarray containing 48 different
oropharyngeal squamous cell cancers and analyzed CD3+ T
cells within these tissue cores (by immunohistochemistry). This
study concluded that overall tumors that were classified as
CD3high exhibited decreased rates of metastasis compared to
those that were CD3low. Interestingly, the largest tumors overall
(grade T4) had the lowest CD3 levels. However, when the
tumors were divided between those that were HPV positive and
those that were HPV negative, this finding only held for the
virus positive tumors. Notably, 32/48 tumor specimens had
detectable HPV-16 DNA. Analysis of overall survival in relation
to CD3 content did not show statistical significance. The
limitations of this study include the small number of patients
and the technique for counting the CD3+ cells. The cellular
infiltrate was graded, not counted, and was limited to the tissue
core which represented 0.6 mm of the tumor.
Other investigators have examined specific lymphocytic
infiltration in the context of studies on immunoevasion by
HNSCC. Le et al. (78) identified the hypoxia inducible
production of galectin-1 in the supernatants of squamous cell
carcinoma cell lines. As galectin-1 has been shown to have
apoptotic effects on T cells, these investigators examined CD3+
T cell infiltration in 101 HNSCCs and found that there was a
significant inverse association between galectin-1 expression
and CD3+ T cell infiltration. In multivariate analysis, either
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Figure 1

Representative histology and IHC for CD3+ T cells in a supraglottic squamous cell carcinoma. (A) H&E stained section showing lymphocytic infiltrate, particularly
prominent at the periphery of large tumor nests (200x). (B) Low power (200x) view of CD3+ T cell infiltration in peritumoral stroma and into the periphery of large
tumor nests. (C) High power (400x) view of CD3+ T cell IHC. Abbreviations: P, peritumoral; I, intratumoral.

strong galectin-1 staining or weak CD3+ T cell staining
predicted for a poor patient outcome.
CD8+ T cell infiltration and patient outcomes were examined
in two studies which came to opposing conclusions. Ferrone and
colleagues (73) examined antigen processing machinery (APM)
deficiencies in HNSCC as a mechanism of immunoevasion and
also quantified CD8+ T cell infiltration. Using specific
monoclonal antibodies (mAbs) to various APM components,
they analyzed 63 tumor specimens from glottic, supraglottic and
subglottic sites and found LMP2 and HLA class I down
regulation, in addition to decreased CD8+ T cell infiltration,
was correlated with poorer patient outcomes. Decreased class I
molecule expression by tumor cells correlated with decreased
CD8+ T cell infiltration (P < 0.001). CD8+ T cell infiltration was
analyzed by dichotomizing patients into those who had more
than 20 cells/HPF and those that had fewer than 20 cells/HPF
within the tumor. A significant association for cause specific
survival (CSS), but not disease free survival (DFS), was
observed. How CD8+ T cells do not contribute to recurrence but
do contribute to improved cancer-specific survival is unclear. In
addition, as opposed to other TIL studies, this study determined
CD8+ T cell infiltration by counting cells in a 0.25 mm2 area of
tumor (as opposed to the more typical 10-20 HPFs) and the
survival curve analysis did not examine CD8+ T cells as a
continuous variable. Notwithstanding these comments, the
significant correlation between decreased APM components in
tumors and decreased CD8+ T cell infiltration does suggest that
tumor antigens being presented in the context of HLA class I are
being recognized by specific immune components which impact
on survival.
In contrast to the study of Ferrone and colleagues (73),
Badoual et al. (86) reported that CD4+ T cell, but not CD8+ T
cell, infiltration was significantly correlated with patient
survival. They examined tissue from 84 patients with HNSCC
arising from 5 different subsites with the majority of tumors (47/
84; 56%) being stage T3 or T4 and the majority of patients (44/
84; 52%) having regional lymph node metastasis. Surprisingly,
analysis of intratumoral and stromal regions did not reveal an
association between CD8+ T cell infiltration and locoregional
control or overall survival. As expected, better locoregional
control and overall survival was observed with lower T stage in
multivariate analysis. Interestingly, better locoregional control
was observed with increased numbers of CD4+ FoxP3+
regulatory T cells, which the authors postulate decrease local
inflammation thus impeding tumor growth. This finding is in
contrast to studies in ovarian cancer, where the presence of
regulatory T cells bode poorly for patients (87). For overall
survival, only the presence of increased numbers of CD4+
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CD69+ activated phenotype T cells correlated with improved
patient outcomes. Thus, this study is the first to correlate CD4+
CD69+ T cells in TILs as a positive prognostic factor for overall
survival.
Finally, our own analysis (JSL and RU, unpublished) of over 35
supraglottic squamous cell carcinomas did not identify any
correlation between specific CD3+, CD4+ or CD8+ T cell
infiltration and survival. We counted 10 HPFs per tumor and
performed statistical analysis using these counts as a continuous
variable. A representative section of immunohistochemistry for
CD3+ T cells infiltrating a supraglottic squamous cell tumor is
shown in Figure 1.

Additional immune cell subsets within HNSCC
Although the focus on TILs implies antigen-specific
infiltrating cells, other adaptive and innate hematopoietic cells
contribute to the HNSCC tumor microenvironment and several
reports have addressed their possible contribution to tumor
behavior (64, 76, 88, 89). These other cellular subsets include
myeloid-derived suppressor cells (MDSCs), FoxP3+ regulatory
CD4+ T cells, tumor-associated macrophages (TAMs) and
plasmacytoid dendritic cells (pDCs). MDSCs in mice are a bone
marrow-derived Gr-1+ CD11b+ immature myeloid population
that has been shown to inhibit T cell responses by several
mechanisms, including expressing arginase I which deprives T
cells of the critical amino acid arginine [reviewed in (63)].
HNSCC was one of the first human cancers where similar cells
were identified as CD34+ progenitor cells that inhibited T cell
responses (70, 90) and in a small analysis were shown to
correlate with poor patient outcomes (91). Further, analysis of
these cells in HNSCC has been limited. A second major
immunosuppressive subset of cells are regulatory CD4+ T cells
that express the forkhead/winged-helix transcription factor
FoxP3 and at least in part mediate their actions via IL-10 and
TGF-β. Whiteside and colleagues (76) have identified these cells
in the peripheral blood and TILs of patients with HNSCC.
Interestingly, these cells persist in the peripheral blood after
complete tumor eradication in patients with no evidence of
disease. As detailed above and in contrast to the studies of Curiel
and colleagues (87), Badoual et al. (86) found that Treg
infiltration into tumors was correlated with better locoregional
control.
Macrophage infiltration into tumors including breast, prostate
and bladder has been shown to correlate with poor patient
prognosis [reviewed in (92)]. Similarly, Teknos and colleagues
(89) examined 102 oral cavity HNSCCs and identified that
TAMs were correlated with an increased propensity for tumors
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to exhibit regional metastatic capacity and extracapsular
extension, which are known risk factors for worse patient
outcomes. Interestingly, this connection also held true for
smaller grade T1 or T2 tumors where regional metastasis is seen
less frequently than in advanced tumors. Further mechanistic
exploration of how macrophages may promote regional
metastatic activity has not been explored in HNSCC.

Concluding remarks

As we analyzed the literature in preparing this review, it
became apparent that no definitive studies exist either
supporting or dismissing the prognostic relevance of TIL
analysis in HNSCC. As with many studies on human cancer, a
limited number of samples and diverse stages and subsites
clouds the interpretation of the available data. In addition, the
very recent appreciation of HPV-associated HNSCC as a
relatively distinct clinical entity necessitates a reanalysis of TIL
studies with viral infection as a dichotomizing variable. The
significant implications of virus-associated HNSCC and other
points highlighted in this review indicate arenas for future work
on the important topic of TILs and HNSCC solid tumor biology.
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